- Home
- SPRO vs SCPH Comparison
SPRO vs SCPH Comparison
Compare SPRO & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- SCPH
- Stock Information
- Founded
- SPRO 2013
- SCPH 2013
- Country
- SPRO United States
- SCPH United States
- Employees
- SPRO N/A
- SCPH N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- SCPH Health Care
- Exchange
- SPRO Nasdaq
- SCPH Nasdaq
- Market Cap
- SPRO 162.1M
- SCPH 173.6M
- IPO Year
- SPRO 2017
- SCPH 2017
- Fundamental
- Price
- SPRO $2.18
- SCPH $5.25
- Analyst Decision
- SPRO Buy
- SCPH Strong Buy
- Analyst Count
- SPRO 4
- SCPH 3
- Target Price
- SPRO $5.00
- SCPH $14.00
- AVG Volume (30 Days)
- SPRO 784.3K
- SCPH 315.0K
- Earning Date
- SPRO 08-12-2025
- SCPH 08-13-2025
- Dividend Yield
- SPRO N/A
- SCPH N/A
- EPS Growth
- SPRO N/A
- SCPH N/A
- EPS
- SPRO N/A
- SCPH N/A
- Revenue
- SPRO $44,584,000.00
- SCPH $41,982,000.00
- Revenue This Year
- SPRO N/A
- SCPH $108.95
- Revenue Next Year
- SPRO N/A
- SCPH $73.83
- P/E Ratio
- SPRO N/A
- SCPH N/A
- Revenue Growth
- SPRO N/A
- SCPH 138.10
- 52 Week Low
- SPRO $0.51
- SCPH $1.94
- 52 Week High
- SPRO $3.22
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- SPRO 32.49
- SCPH 63.11
- Support Level
- SPRO $2.30
- SCPH $5.37
- Resistance Level
- SPRO $2.45
- SCPH $6.28
- Average True Range (ATR)
- SPRO 0.11
- SCPH 0.31
- MACD
- SPRO -0.07
- SCPH 0.04
- Stochastic Oscillator
- SPRO 2.03
- SCPH 47.72
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.